BAG5
protein-codingBAG cochaperone 5, the group of BAG cochaperones
Gene summary
The protein encoded by this gene is a member of the BAG1-related protein family. BAG1 is an anti-apoptotic protein that functions through interactions with a variety of cell apoptosis and growth related proteins including BCL-2, Raf-protein kinase, steroid hormone receptors, growth factor receptors and members of the heat shock protein 70 kDa family. This protein contains a BAG domain near the C-terminus, which could bind and inhibit the chaperone activity of Hsc70/Hsp70. Three transcript variants encoding two different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~6.1 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0030680
Submitter: Ambry Genetics
Inheritance Pattern: AR
Disease ID:MONDO:0030680
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AR
Disease ID:MONDO:0030680
Submitter: ClinGen
BAG5 was evaluated for autosomal recessive dilated cardiomyopathy (DCM). BAG5, first described in 1999 (Takayama et al., 1999, PMID: 9873016), is a part of the BAG family of co-chaperones for Hsp70 and Hsc70 aiding in protein folding and trafficking regulation. At the time of review, dilated cardiomyopathy is the only condition that has been associated with this gene. Human genetic evidence supporting this gene-disease relationship includes case-level data. At least 5 variants (nonsense, frameshift) have been reported in humans with DCM in a homozygous or compound heterozygous state. A total of 12 cases across 5 primary publications were reviewed. Two publications from Hakui et al. (Hakui et al., 2022, PMID: 35044787; Hakui et al., 2022, PMID: 36130910) detail 6 of the total reported cases reviewed. In addition, the BAG5 p.Arg197Ter variant first detailed in Hakui et al. 2022 was reported in 6 of the 12 cases reviewed across 3 primary publications in either a homozygous (Hakui et al., 2022, PMID: 35044787; Hakui et al., 2022, PMID: 36130910) or compound heterozygous state (Inoue et al., 2023, PMID: 37873655). While consanguinity was unknown for the homozygous cases, 3 of these cases were identified querying 536 DCM patients in an in-house Japanese database after transcriptomics identified BAG5 as an upregulated gene in tissue from DCM patients compared to controls (Hakui et al, 2022, PMID: 35044787). Frequency of this variant in a small, geographically isolated population suggests a possible founder variant. BAG5 loss-of-function variants were identified in remaining DCM proband cases via whole exome (Inoue et al., 2023, PMID: 37873655; Hakui et al., 2022, PMID 36130910; Wongwong et al., 2024, PMID: 38796549) or whole genome sequencing (Lesurf et al., 2022, PMID: 3588587). While majority of the 12 cases reviewed were from independent families, Wongwong et al., 2024 detailed clinical and genetic evidence from a large, consanguineous, Middle Eastern kindred with whole exome sequencing in 3 affected siblings and 2 unaffected parents, identifying a frameshift BAG5 variant consistent with biallelic loss-of-function. Sanger sequencing in nine additional relatives showed segregation of the variant with normal clinical phenotypes in a heterozygous or wild-type state (Wongwong et al., 2024, PMID: 38796549). In addition, this gene-disease assertion is supported by recapitulated disease phenotypes in animal models with phenotypic rescue, and functional data supporting protein-interaction with a previously curated, moderate-DCM gene, JPH2. Knock-in (KI) homozygous mice harboring the previously detailed p.Arg197Ter variant were created utilizing CRISPR-CAS9 methodology (Hakui et al., 2022, PMID: 35044787). Cardiac phenotypes of homozygous KI-mice were compared to wild-type mice via cardiac magnetic resonance imaging at 12 weeks and echocardiogram imaging from 5 to 12 weeks, identifying a phenotype consistent with DCM. Phenotypic rescue after administration of AAV9 vector carrying wild-type BAG5 and cardiac troponin T promoter (administered at 10 weeks) was successfully demonstrated with significant improvements in left ventricular diastolic diameter (reduction) and fractional shortening (increase) via echocardiogram at 12 weeks of age. Finally, a series of co-immunoprecipitations with HEK239T cells (harboring a different human variant, p.Arg390Ter) and isolated cardiomyocytes from the previously described mouse-model were completed to investigate interaction of specific substrates with the HSC70/BAG5 complex (Hakui et al., 2022, PMID 35044787). Utilizing primary HSC70 antibodies, co-IP experiments with wild-type and mutant HEK293T cells and co-IP experiments with wild-type and mutant isolated cardiomyocytes from the KI-mice model indicated reduced pull down of HSC70 and reduced pull down of JPH2 when mutant BAG5 was present. This data supports indirect interaction of BAG5 with JPH2 through the HSC70/BAG5 complex. In summary, there is moderate evidence to support this gene-disease relationship. More evidence is needed to establish the relationship of BAG5 with AR-DCM definitively. This classification was approved by the ClinGen Dilated Cardiomyopathy Working Group on 6/14/2024 (SOP Version 10).
Inheritance Pattern: AR
Disease ID:MONDO:0030680
Submitter: PanelApp Australia
Clinical Genomic Database (CGD)
Manifestation: Cardiovascular
Intervention: Cardiovascular
Rationale: The condition can involve cardiomyopathy and arrhythmia, and surveillance (eg, with echocardiogram and electocardiogram) may allow early detection and management (eg, the use of LVAD has been described) of manifestations, which may be beneficial
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to BAG5 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_001015048.3. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 3 | 3 | ||||
| missense | 60 | 4 | 64 | |||
| nonsense | 1 | 1 | 2 | |||
| start loss | 0 | |||||
| frameshift | 1 | 2 | 2 | 5 | ||
| splice donor/acceptor (+/-2bp) | 0 | |||||
| Total | 2 | 3 | 62 | 7 | 0 | 74 |
Highest pathogenic variant AF is 0.00001504928
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_001015048.1 | 1 | MANE Select | |
| Ensembl | ENSP00000299204.4 | 1 | MANE Select | |
| RefSeq | NP_001015049.2 | 1 | Standard | |
| RefSeq | NP_004864.1 | 1 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Regulation of HSF1-mediated heat shock response
- Cellular responses to stress
- Cellular responses to external stimuli
- Cellular response to heat stress
Biological Process
- protein folding
- Golgi organization
- negative regulation of neuron projection development
- negative regulation of protein ubiquitination
- negative regulation of proteasomal ubiquitin-dependent protein catabolic process
Molecular Function
- adenyl-nucleotide exchange factor activity
- protein binding
- protein kinase binding
- ubiquitin protein ligase binding
- chaperone binding
Cellular Component
- nucleus
- mitochondrion
- cytosol
- membrane
- inclusion body
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000337322
- Coding exons
- 2
- Length
- 6288
- Individuals with no LoFs
- 125708
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 40
- Defined
- 125748
- p
- 0.000159
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 0.372 | 240 | 257 | 0.935 | 0.0000146 | 3229 |
| Missense (PolyPhen) | 69 | 82.803 | 0.8333 | 1120 | ||
| Synonymous | -0.0767 | 104 | 103 | 1.01 | 0.00000621 | 931 |
| Loss of Function | 1.10 | 11 | 15.7 | 0.700 | 8.36e-7 | 208 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.00025 | 0.00025 | rare |
| Latino/Admixed American | 0.00012 | 0.00012 | rare |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0.00033 | 0.00033 | rare |
| Finnish | 0.000094 | 0.000092 | rare |
| European (Non-Finnish) | 0.00016 | 0.00016 | rare |
| South Asian | 0.00020 | 0.00020 | rare |
| Other | 0 | 0.0 | absent |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Inhibits both auto-ubiquitination of PRKN and ubiquitination of target proteins by PRKN (By similarity). May function as a nucleotide exchange factor for HSP/HSP70, promoting ADP release, and activating Hsp70-mediated refolding. {ECO:0000250, ECO:0000269|PubMed:20223214}.;
Recessive Scores
- pRec
- 0.204
Intolerance Scores
- LoFtool
- 0.185
- RVIS EVS
- -0.07
- RVIS percentile EVS
- 48.54
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Essential (gene trap)
- N
- Indispensability pred.
- E
- Indispensability score
- 0.756
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |